October 16, 2006 -- In November 1997, Rituxan was approved in the US as the first monoclonal antibody for cancer. Since its inception, Rituxan, which is the result of a collaboration between Biogen Idec and Genentech, has steadily expanded its application in cancer and recently added rheumatoid arthritis to its indications. But sales slipped lower in the third quarter, despite the expansion of the label. We look at the diminishing growth prospects for this blockbuster drug...
